Physician profile
Joseph Mignone
NPI 1154318012
$6,223.50
in general payments reported to CMS, 2019-2025
32 companies · $834 in 2025
The $834 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,467 · 2020: $72.25 · 2021: $432 · 2022: $176 · 2023: $587 · 2024: $655 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,747 · Education: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,746.67 |
| Education | $329.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,383.65 | 2019-2025 | Tagrisso, Imfinzi, Datroway |
| Daiichi Sankyo INC. | $607.43 | 2021-2025 | Enhertu, Datroway |
| Glaxosmithkline, LLC. | $237.06 | 2021-2025 | Jemperli |
| Pfizer INC. | $232.52 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $230.04 | 2021-2024 | Ultomiris |
| Amgen INC. | $194.48 | 2019-2025 | Imdelltra (Amg757) |
| E.R. Squibb & Sons, L.L.C. | $192.89 | 2019-2024 | Opdivo, Eliquis |
| Merck Sharp & Dohme LLC | $132.23 | 2019-2025 | Keytruda |
| Eisai INC. | $87.48 | 2022 | |
| Stemline Therapeutics INC. | $79.08 | 2023-2025 | Orserdu |
| Rigel Pharmaceuticals, INC. | $75.24 | 2022 | |
| Incyte Corporation | $73.99 | 2021 | |
| Lilly USA, LLC | $69.77 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $68.78 | 2019-2023 | Venclexta, Gazyva, Polivy |
| Foundation Medicine, INC. | $60.26 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $59.21 | 2019-2023 | |
| Exelixis INC. | $51.43 | 2019-2022 | |
| Emd Serono, INC. | $43.88 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.90 | 2019 | |
| Tesaro, INC. | $38.50 | 2019 | |
| Celgene Corporation | $35.86 | 2020-2025 | Reblozyl |
| Gilead Sciences, INC. | $35.18 | 2019-2021 | |
| Janssen Biotech, INC. | $34.51 | 2021-2023 | Rybrevant |
| Seagen INC. | $32.18 | 2023 | Adcetris |
| Astellas Pharma US INC | $21.71 | 2023 | Xospata |
| Lexicon Pharmaceuticals, INC. | $16.84 | 2019 | |
| Caris Mpi, INC. | $16.17 | 2025 | Mi Cancer Seek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.10 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.03 | 2020 | |
| Genzyme Corporation | $14.95 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $14.70 | 2024 | Onivyde, Somatuline Depot |
| Aurobindo Pharma USA, INC. | $13.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Mignone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.